A novel Css-MRTpo approach to simulate oral plasma concentration–time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite in humans using chimeric mice with humanized livers

References

• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5.
   PubMed Web of Science ®Google Scholar
• Di L, Feng B, Goosen TC, et al. (2013). A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos 41:1975–93.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. (2009). ICH topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. London (UK): European Medicines Agency.
   Google Scholar
• Food and Drug Administration. (2016). Guidance for industry: safety testing of drug metabolites. Silver Spring (MD): US Department Health and Human Services FaDA, Center for Drug Evaluation and Research.
   Google Scholar
• Fura A, Vyas V, Humphreys W, et al. (2008). Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compounds. Biopharm Drug Dispos 29:455–68.
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Kawai K, Mitsui T, et al. (2011). The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun 405:405–10.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S. (2016). Assessment of chimeric mice with humanized livers in new drug development: generation of pharmacokinetics, metabolism and toxicity data for selecting the final candidate compound. Xenobiotica 46:557–69.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Chijiwa H, et al. (2017). Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling. Xenobiotica 47:382–93.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Ito S, Nozawa K, et al. (2015). Formation of the accumulative human metabolite and human-specific glutathione conjugate of diclofenac in TK-NOG chimeric mice with humanized livers. Drug Metab Dispos 43:309–16.
   PubMed Web of Science ®Google Scholar
• Kamimura H, Nakada N, Suzuki K, et al. (2010). Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab Pharmacokinet 25:223–35.
   PubMed Web of Science ®Google Scholar
• Kato K, Ohbuchi M, Hamamura S, et al. (2015). Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver. Drug Metab Dispos 43:1208–17.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, et al. (2004). Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab Dispos 32:1402–10.
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Okumura H, et al. (2005). Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 33:1333–40.
   PubMed Web of Science ®Google Scholar
• Katoh M, Yokoi T. (2007). Application of chimeric mice with humanized liver for predictive ADME. Drug Metab Rev 39:145–57.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis G, de Kanter R. (2006). Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine. Drug Metab Dispos 34:1047–54.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2017). Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica 47:1052–63.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, et al. (2019). Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. Xenobiotica 49:1379–87.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Ito S, Suzuki M, et al. (2019). Prediction of human pharmacokinetics of typical compounds by a physiologically based method using chimeric mice with humanized liver. Xenobiotica 49:404–14.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. (2018). Chimeric mice with humanized liver: Application in drug metabolism and pharmacokinetics studies for drug discovery. Drug Metab Pharmacokinet 33:31–9.
   PubMed Web of Science ®Google Scholar
• Naritomi Y, Sanoh S, Ohta S. (2019). Utility of chimeric mice with humanized liver for predicting human pharmacokinetics in drug discovery: Comparison with in Vitro-in Vivo Extrapolation and Allometric Scaling. Biol Pharm Bull 42:327–36.
   PubMed Web of Science ®Google Scholar
• Nguyen HQ, Lin J, Kimoto E, et al. (2017). Prediction of losartan-active carboxylic acid metabolite exposure following losartan administration using static and physiologically based pharmacokinetic models. J Pharm Sci 106:2758–70.
   PubMed Web of Science ®Google Scholar
• Obach RS, Lin J, Kimoto E, et al. (2018). Estimation of circulating drug metabolite exposure in human using in vitro data and physiologically based pharmacokinetic modeling: example of a high metabolite/parent drug ratio. Drug Metab Dispos 46:89–99.
   PubMed Web of Science ®Google Scholar
• Ohtsuki S, Kawakami H, Inoue T, et al. (2014). Validation of uPA/SCID mouse with humanized liver as a human liver model: protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases by LC-MS/MS. Drug Metab Dispos 42:1039–43.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn JA, Guzman-Perez A, Oates PJ, et al. (2011). Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl) benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. Med Chem Commun 2:828–39.
   Web of Science ®Google Scholar
• Poulin P, Haddad S. (2013). Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J Pharm Sci 102:3239–51.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Horiguchi A, Sugihara K, et al. (2012). Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab Dispos 40:322–8.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Naritomi Y, Fujimoto M, et al. (2015). Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver. Xenobiotica 45:605–14.
   PubMed Web of Science ®Google Scholar
• Sanoh S, Ohta S. (2014). Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics. Biopharm Drug Dispos 35:71–86.
   PubMed Web of Science ®Google Scholar
• Sawada T, Yamaura Y, Higuchi S, et al. (2019). Predicting successful/unsuccessful extrapolation for in vivo total clearance of model compounds with a variety of hepatic intrinsic metabolism and protein bindings in humans from pharmacokinetic data using chimeric mice with humanised liver. Xenobiotica.
   PubMed Web of Science ®Google Scholar
• Schadt S, Bister B, Chowdhury SK, et al. (2018). A decade in the MIST: learnings from investigations of drug metabolites in drug development under the “Metabolites in Safety Testing” regulatory guidance. Drug Metab Dispos 46:865–78.
   PubMed Web of Science ®Google Scholar
• Sharma R, Litchfield J, Atkinson K, et al. (2014). Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator. Drug Metab Dispos 42:1926–39.
   PubMedGoogle Scholar
• Tateno C, Miya F, Wake K, et al. (2013). Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 93:54–71.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901–12.
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Marathe P, He H, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100:4111–26.
   PubMed Web of Science ®Google Scholar
• Wajima T, Yano Y, Fukumura K, Oguma T. (2004). Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci 93:1890–900.
   PubMed Web of Science ®Google Scholar
• Yau E, Petersson C, Dolgos H, Peters SA. (2017). A comparative evaluation of models to predict human intestinal metabolism from nonclinical data. Biopharm Drug Dispos 38:163–86.
   PubMed Web of Science ®Google Scholar
• Zhang T, Heimbach T, Lin W, et al. (2015). Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds. J Pharm Sci 104:2795–806.
   PubMed Web of Science ®Google Scholar